RESUMEN

To the Editor, In 1998 Sildenafil was approved by the Food and Drug Administration as first line therapy for erectile dysfunction. Since then, phosphodiesterase type 5 inhibitors (PDE5i) represent the first-line treatment of erectile dysfunction (ED), improving physiological erectile function, sexual orgasmic function, psychological self-esteem, couples' relationship, and quality of life. [...].

Asunto(s)

Disfunción Eréctil , Inhibidores de Fosfodiesterasa 5 , Citrato de Sildenafil , Disfunción Eréctil/tratamiento farmacológico , Disfunción Eréctil/psicología , Humanos , Masculino , Inhibidores de Fosfodiesterasa 5/uso terapéutico , Citrato de Sildenafil/uso terapéutico , Calidad de Vida